Center for Health and Biological Sciences, Pontifícia Universidade Católica do Paraná, Curitiba-PR, Brazil.
J Am Soc Nephrol. 2011 Oct;22(10):1939-45. doi: 10.1681/ASN.2010121306. Epub 2011 Aug 18.
There is growing concern about the development of antibacterial resistance with the use of antibiotics in catheter lock solutions. The use of an antibiotic that is not usually used to treat other serious infections may be an alternative that may reduce the clinical impact should resistance develop. We conducted a randomized controlled trial to compare a solution of minocycline and EDTA with the conventional unfractionated heparin for the prevention of catheter-related bacteremia in hemodialysis patients during a period of 90 d. The study included 204 incident catheters (27.8% tunneled); 14 catheters were excluded because of early dysfunction and 3 because of protocol violations. We observed catheter-related bacteremia in 19 patients in the heparin group (4.3 per 1000 catheter-days) and in 5 patients in the minocycline-EDTA group (1.1 per 1000 catheter-days; P = 0.005). We did not detect a significant difference in the rate of catheter removal for dysfunction. Catheter-related bacteremia-free survival was significantly higher in the minocycline-EDTA group than in the heparin group (P = 0.005). In conclusion, a minocycline-EDTA catheter lock solution is effective in the prevention of catheter-related bacteremia in hemodialysis patients.
人们越来越关注在导管封管液中使用抗生素导致的抗菌耐药性的发展。使用一种通常不用于治疗其他严重感染的抗生素可能是一种替代方案,如果出现耐药性,可能会降低临床影响。我们进行了一项随机对照试验,比较了米诺环素和 EDTA 溶液与常规未分馏肝素在 90 天内预防血液透析患者导管相关性菌血症的效果。该研究纳入了 204 例新置导管(27.8%为隧道式);14 例导管因早期功能障碍而被排除,3 例因违反方案而被排除。肝素组有 19 例患者发生导管相关性菌血症(每 1000 导管日 4.3 例),米诺环素-EDTA 组有 5 例(每 1000 导管日 1.1 例;P = 0.005)。我们未发现导管功能障碍所致导管拔除率的显著差异。米诺环素-EDTA 组的导管相关性菌血症无事件生存率显著高于肝素组(P = 0.005)。总之,米诺环素-EDTA 导管封管液可有效预防血液透析患者的导管相关性菌血症。